Quick Takeaways
- Caligan Partners LP filed SCHEDULE 13D/A for Verrica Pharmaceuticals Inc. Common Stock, par value $0.0001 per share (VRCA).
- Disclosed ownership: 10%.
- Date of event: 26 Dec 2025.
Caligan Partners LP - 26 Dec 2025 SCHEDULE 13D/A Report for Verrica Pharmaceuticals Inc. Common Stock, par value $0.0001 per share (VRCA)
- Filing Manager
- Caligan Partners LP
- Reporting Manager
- Caligan Partners LP
- Symbol
- VRCA
- Shares outstanding
- 65,095,636 shares
- Disclosed Ownership
- 6,503,054 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13D/A
- Filing time
- 30 Dec 2025, 07:10:47 UTC
- Date of event
- 26 Dec 2025
- Previous filing
- 24 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Caligan Partners LP disclosed 10% ownership in Verrica Pharmaceuticals Inc. Common Stock, par value $0.0001 per share (VRCA) on 26 Dec 2025."
What Changed
- Previous schedule filing date: 24 Nov 2025.
- Current filing was accepted on 30 Dec 2025, 07:10.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Caligan Partners LP | 10% | 6,503,054 | 0 | 6,503,054 | /s/ David Johnson | David Johnson, Managing Partner | 0001727492 |
| David Johnson | 10% | 6,503,054 | 0 | 6,503,054 | /s/ David Johnson | David Johnson, Individually | 0001785557 |